Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

NCT03012061 | Completed Phase 2 Results FDA Drug

• 2 other identifiers: 2058322016-002843-40
• Study Type: interventional
• Target: 425
• Locations: 5 countries
• Sites: 70

Brief Summary

This study is conducted to evaluate the effects of UMEC 62.5 microgram (mcg) and UMEC 31.25 mcg on lung function versus placebo after 24 weeks of treatment. This study will provide important information regarding the efficacy and safety of UMEC when administered in a separate inhaler to subjects on a background of fluticasone furoate (FF). This is a Phase IIb, randomized, double-blind, placebo controlled study that will compare the efficacy, safety and tolerability of UMEC (62.5 mcg and 31.25 mcg) administered once-daily in subjects with asthma that is not well controlled. Eligible subjects will be requested to participate in the study for a maximum of approximately 31 weeks with 4 phases (pre screening, screening/run-in, randomization/treatment and safety follow-up). The total number of randomized subjects required is approximately 384, with 128 subjects randomized 1:1:1 to each of the 3 double-blind treatment arms.

Conditions

Asthma

Keywords

Respiratory; Efficacy; Umeclidinium bromide; Parallel; Asthma; Dry powder inhaler

Outcome Measures

Primary Outcomes (1)

• Mean Change From Baseline in Clinic Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24

  FEV1 is measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The highest of 3 technically acceptable measurements were recorded at each Visit. The Baseline value of clinic FEV1 was last acceptable/borderline acceptable (pre-dose) FEV1 value obtained prior to randomized treatment start date. Change from Baseline was calculated as FEV1 value at Week 24 minus FEV1 value at Baseline. Treatment policy estimand was assessed, including all on- and post-treatment data. Intent-to-Treat Population comprised all randomized participants, excluding those who were randomized in error, who did not receive the study drug. Least square (LS) mean and standard error (SE) data is presented. Different participants may have been analyzed at different time points; thus, overall number of participants analyzed reflects everyone in ITT Population without missing covariate information, with Baseline, at least one post-Baseline measurement.

  Baseline (Day 1 pre-dose) and Week 24

Secondary Outcomes (5)

• Mean Change From Baseline in Clinic FEV1 at 3 Hours Post Dose at Week 24

  Baseline (Day 1 pre-dose) and Week 24

• Number of Participants With On-treatment Adverse Events (AE), Non-serious Adverse Events (Non-SAE)

  Up to Week 24

• Number of Participants With On-treatment Abnormal Electrocardiograms (ECG) Findings

  Week 4 and Week 24

• Mean Change From Baseline in On-treatment Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

  Baseline (Day 1 pre-dose), Weeks 4, 12 and 24

• Mean Change From Baseline in On-treatment Pulse Rate

  Baseline (Day 1 pre-dose), Weeks 4, 12 and 24

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Subjects will be administered placebo once daily via the ELLIPTA® dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks. ELLIPTA is a registered trademark of the GSK group of companies.

Drug: Placebo; Drug: Fluticasone Furoate; Drug: Albuterol/salbutamol

UMEC 62.5 mcg

EXPERIMENTAL

Subjects will be administered UMEC 62.5 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.

Drug: UMEC; Drug: Fluticasone Furoate; Drug: Albuterol/salbutamol

UMEC 31.25 mcg

EXPERIMENTAL

Subjects will be administered UMEC 31.25 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.

Drug: UMEC; Drug: Fluticasone Furoate; Drug: Albuterol/salbutamol

Interventions

Placebo DRUG

Placebo is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, both of which contains lactose monohydrate blended with magnesium stearate.

Placebo

UMEC DRUG

UMEC is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GSK573719 blended with lactose blended with magnesium stearate and another one contains lactose monohydrate blended with magnesium stearate.

UMEC 31.25 mcg; UMEC 62.5 mcg

Fluticasone Furoate DRUG

FF is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GW685698 blended with lactose monohydrate and another one contains lactose monohydrate with magnesium stearate.

Placebo; UMEC 31.25 mcg; UMEC 62.5 mcg

Albuterol/salbutamol DRUG

Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.

Placebo; UMEC 31.25 mcg; UMEC 62.5 mcg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age or older at the time of signing the informed consent.
• Subjects with a diagnosis of asthma as defined by the National Institutes of Health at least 6 months prior to Visit 0.
• Asthma Control Questionnaire (ACQ)-6 total score of \>0.75 at Visit 1.
• Subjects are eligible if they have required daily Inhaled Corticosteroids (ICS) therapy \>=100 milligram per day (mg/day) fluticasone propionate (FP) or equivalent with or without Long-Acting Beta-2-Agonists (LABA) or Long-Acting Muscarinic Antagonist (LAMA) for at least 12 weeks prior to Visit 0 and there have been no changes in maintenance asthma medications during the 4 weeks immediately prior to Visit 0. Dosing regimen (once or twice daily to equal the total daily dose) should be restricted to the current local product labels.
• A best pre-bronchodilator morning FEV1 \<=85% of the predicted normal value. Predicted values will be based upon the European Respiratory Society (ERS) Global Lung Function Initiative. A best post-bronchodilator FEV1/ forced vital capacity (FVC) \>=0.7 at Visit 1.
• Airway reversibility is defined as \>=12% and \>=200 mL increase in FEV1 between 20 and 60 minutes following 4 inhalations of albuterol/salbutamol aerosol at Visit 1. Note: If the subject does not meet the above reversibility criteria at Visit 1 then the reversibility assessment may be repeated once within 7 days of Visit 1 if either criteria are met: The \>=9% increase in FEV1 between 20 and 60 minutes following 4 inhalations of albuterol/salbutamol aerosol at Visit 1; Documented evidence of a reversibility assessment within 1 year prior to Visit 1 which demonstrated a post-bronchodilator increase in FEV1 of \>=12% and \>=200 milliliter (mL). Should the subject successfully demonstrate airway reversibility (defined as \>=12% and \>=200 mL increase in FEV1 between 20 and 60 minutes following 4 inhalations of albuterol/salbutamol aerosol) at the second attempt then, provided that all other eligibility criteria assessed at Visit 1 are met, the subject may enter the 2-week run-in period.
• All subjects must be able to replace their current Short-Acting Beta-2-Agonists (SABA) inhaler with albuterol/salbutamol aerosol inhaler at Visit 1 as needed for the duration of the study. Subjects must be judged capable of withholding albuterol/salbutamol for at least 6 hours prior to study visits.
• Both male and female subjects are eligible to participate in the study. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 5 days after the last dose of study treatment.
• Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form and in this protocol. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials.
• ACQ-6 total score of \>0.75 at Visit 2.
• Spirometry: A best pre-bronchodilator morning FEV1 \<=85% of the predicted normal value at Visit 2. Predicted values will be based upon the ERS Global Lung Function Initiative.
• Alanine aminotransferase (ALT) \<=2 x upper limit of normal (ULN). Alkaline phosphatase \<=1.5 x ULN. Bilirubin \<=1.5 x ULN (isolated bilirubin \>1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
• Compliance with completion of the Daily electronic diary (eDiary) reporting defined as completion of all questions/assessments on \>=4 of the last 7 days during the run-in period.

You may not qualify if:

• Chest X-ray documented pneumonia in the 12 weeks prior to Visit 1.
• Any severe asthma exacerbation, defined as deterioration of asthma requiring the use of systemic corticosteroids (oral, parenteral or depot) within 12 weeks of Visit 1, or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids within 12 weeks of Visit 1.
• Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, lung cancer, or other respiratory abnormalities other than asthma.
• Women who are pregnant or lactating or are planning to become pregnant during the study.
• Immune suppression (e.g., Human Immunodeficiency Virus \[HIV\], Lupus) or other risk factors for pneumonia (e.g., neurological disorders affecting control of the upper airway, such as Parkinson's disease, Myasthenia Gravis). Subjects at potentially high risk (e.g., very low Body Mass Index \[BMI\], severely malnourished, or very low FEV1) will only be included at the discretion of the Investigator
• Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
• Unstable liver disease as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Note: Chronic stable hepatitis B and C is acceptable if the subject otherwise meets entry criteria.
• Evidence of a clinically significant abnormality in the 12-lead ECG performed during screening or run-in. The Principal Investigator will determine the clinical significance of each abnormal ECG finding in relation to the subject's medical history and exclude subjects who would be at undue risk by participating in the trial. An abnormal and clinically significant finding is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following: Atrial fibrillation (AF) with rapid ventricular rate \>120 beats per minute (BPM); Sustained or nonsustained ventricular tachycardia (VT); Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted); QT interval corrected for heart rate by Fridericia's formula (QTcF) \>=500 millisecond (msec) in subjects with QRS \<120 msec and QTcF \>=530 msec in subjects with QRS \>=120 msec.
• Subjects with any of the following at Screening (Visit 1) would be excluded: Myocardial infarction or unstable angina in the last 6 months; Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months; New York Heart Association (NYHA) Class IV Heart failure.
• Subjects with a medical condition such as narrow-angle glaucoma, urinary retention, prostatic hypertrophy or bladder neck obstruction should only be included if in the opinion of the Investigator the benefit outweighs the risk and that the condition would not contraindicate study participation.
• Subjects with carcinoma that has not been in complete remission for at least 5 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the subject has been considered cured by treatment.
• Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study.
• Subjects who are medically unable to withhold their albuterol/salbutamol for the 6-hour period required prior to spirometry testing at each study visit.
• Current smoker or a smoking history of \>=10 pack years (e.g., 20 cigarettes/day for 10 years). A subject may not have used inhaled tobacco products within the past 12 months (i.e., cigarettes, e-cigarettes/vaping, cigars or pipe tobacco).
• Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years. This includes marijuana, which is considered an abused drug.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (70)

GSK Investigational Site

Tempe, Arizona, 85283, United States

Location

GSK Investigational Site

Rolling Hills Estates, California, 90274, United States

Location

GSK Investigational Site

Colorado Springs, Colorado, 80907, United States

Location

GSK Investigational Site

Topeka, Kansas, 66606, United States

Location

GSK Investigational Site

Natchitoches, Louisiana, 71457, United States

Location

GSK Investigational Site

Sunset, Louisiana, 70584, United States

Location

GSK Investigational Site

North Dartmouth, Massachusetts, 02747, United States

Location

GSK Investigational Site

Minneapolis, Minnesota, 55402, United States

Location

GSK Investigational Site

Monroe, North Carolina, 28112, United States

Location

GSK Investigational Site

Raleigh, North Carolina, 27607, United States

Location

GSK Investigational Site

Shelby, North Carolina, 28150, United States

Location

GSK Investigational Site

Cincinnati, Ohio, 45231, United States

Location

GSK Investigational Site

Cincinnati, Ohio, 45242, United States

Location

GSK Investigational Site

Medford, Oregon, 97504, United States

Location

GSK Investigational Site

Old Point Station, South Carolina, 29707, United States

Location

GSK Investigational Site

Orangeburg, South Carolina, 29118, United States

Location

GSK Investigational Site

Spartanburg, South Carolina, 29303, United States

Location

GSK Investigational Site

Union, South Carolina, 29379, United States

Location

GSK Investigational Site

Dallas, Texas, 75225, United States

Location

GSK Investigational Site

Calgary, Alberta, T2Y 2Z7, Canada

Location

GSK Investigational Site

Vancouver, British Columbia, V5Z 4E1, Canada

Location

GSK Investigational Site

Brampton, Ontario, L6T 0G1, Canada

Location

GSK Investigational Site

Burlington, Ontario, L7N 3V2, Canada

Location

GSK Investigational Site

Corunna, Ontario, N0N 1G0, Canada

Location

GSK Investigational Site

Mississauga, Ontario, L5A 3V4, Canada

Location

GSK Investigational Site

Toronto, Ontario, M9V 4B4, Canada

Location

GSK Investigational Site

Windsor, Ontario, N8X 2G1, Canada

Location

GSK Investigational Site

Montreal, Quebec, H3G 1L5, Canada

Location

GSK Investigational Site

Québec, Quebec, G3K 2P8, Canada

Location

GSK Investigational Site

Bialystok, 15-044, Poland

Location

GSK Investigational Site

Elblag, 82-300, Poland

Location

GSK Investigational Site

Kielce, 25-365, Poland

Location

GSK Investigational Site

Krakow, 30-033, Poland

Location

GSK Investigational Site

Krakow, 31-637, Poland

Location

GSK Investigational Site

Lodz, 90-302, Poland

Location

GSK Investigational Site

Lublin, 20-089, Poland

Location

GSK Investigational Site

Poznan, 60-823, Poland

Location

GSK Investigational Site

Rzeszów, 35-051, Poland

Location

GSK Investigational Site

Sopot, 81-741, Poland

Location

GSK Investigational Site

Tarnów, 33-100, Poland

Location

GSK Investigational Site

Warsaw, 02-777, Poland

Location

GSK Investigational Site

Wroclaw, 54-239, Poland

Location

GSK Investigational Site

Zgierz, 95-100, Poland

Location

GSK Investigational Site

Brasov, 500051, Romania

Location

GSK Investigational Site

Bucharest, 050159, Romania

Location

GSK Investigational Site

Cluj-Napoca, 400162, Romania

Location

GSK Investigational Site

Codlea, 505100, Romania

Location

GSK Investigational Site

Deva, 330084, Romania

Location

GSK Investigational Site

Iași, 700115, Romania

Location

GSK Investigational Site

Piteşti, 110117, Romania

Location

GSK Investigational Site

Râmnicu Vâlcea, 240564, Romania

Location

GSK Investigational Site

Sibiu, 550196, Romania

Location

GSK Investigational Site

Timișoara, 300310, Romania

Location

GSK Investigational Site

Arkhangelsk, 163001, Russia

Location

GSK Investigational Site

Barnaul, 656045, Russia

Location

GSK Investigational Site

Moscow, 115478, Russia

Location

GSK Investigational Site

Moscow, 119021, Russia

Location

GSK Investigational Site

Moscow, 119121, Russia

Location

GSK Investigational Site

Odintsovo, 143005, Russia

Location

GSK Investigational Site

Pyatigorsk, 357538, Russia

Location

GSK Investigational Site

Saint Petersburg, 194356, Russia

Location

GSK Investigational Site

Saint Petersburg, 196240, Russia

Location

GSK Investigational Site

Samara, 443068, Russia

Location

GSK Investigational Site

Smolensk, 214006, Russia

Location

GSK Investigational Site

St'Petersburg, 197706, Russia

Location

GSK Investigational Site

Tomsk, 634 050, Russia

Location

GSK Investigational Site

Volgodonsk, 347382, Russia

Location

GSK Investigational Site

Voronezh, 394018, Russia

Location

GSK Investigational Site

Yaroslavl, 150047, Russia

Location

GSK Investigational Site

Yekaterinburg, 620039, Russia

Location

Related Publications (2)

• Kerwin E, Pascoe S, Bailes Z, Nathan R, Bernstein D, Dahl R, von Maltzahn R, Robbins K, Fowler A, Lee L. A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids. Respir Res. 2020 Jun 12;21(1):148. doi: 10.1186/s12931-020-01400-5.

  PMID: 32532275 BACKGROUND

• Oppenheimer J, Hanania NA, Chaudhuri R, Sagara H, Bailes Z, Fowler A, Peachey G, Pizzichini E, Slade D. Clinic vs Home Spirometry for Monitoring Lung Function in Patients With Asthma. Chest. 2023 Nov;164(5):1087-1096. doi: 10.1016/j.chest.2023.06.029. Epub 2023 Jun 27.

  PMID: 37385337 DERIVED

MeSH Terms

Conditions

Asthma

Interventions

fluticasone furoate; Albuterol

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Intervention Hierarchy (Ancestors)

Ethanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Amines; Phenethylamines; Ethylamines

Results Point of Contact

• Title: GSK Response Center
• Organization: GlaxoSmithKline

GSKClinicalSupportHD@gsk.com

866-435-7343

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 4, 2017
• First Posted: January 6, 2017
• Study Start: January 25, 2017
• Primary Completion: May 30, 2018
• Study Completion: May 30, 2018
• Last Updated: October 28, 2020
• Results First Posted: June 19, 2019

Record last verified: 2020-10

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
• Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Locations

CA (10); RO (10); US (19); RU (17); PL (14)